Progress of immunological surveillance in the treatment-free remission of chronic myelogenous leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 502-505, 2022.
Article
en Zh
| WPRIM
| ID: wpr-953991
Biblioteca responsable:
WPRO
ABSTRACT
With the wide application of tyrosine kinase inhibitor (TKI), to obtain treatment-free remission (TFR) has gradually become the long-term goal for patients with chronic myelogenous leukemia (CML). Self-renewing leukemia stem cells during disease progression are related with the recurrence, and surveillance of residual leukemic cells is hypothesized to be one of the critical factors in successful TFR. On the way to obtain TFR, many breakthroughs have been made in innate and adaptive immunity of CML cells. This paper reviews the immune function of CML patients, the role of the immune markers in maintaining TFR, and the exploration of TKI combined with new immunomodulator therapy to achieve a greater degree of TFR.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2022
Tipo del documento:
Article